BridgeMD
New treatment option for Peripheral Arterial Disease (PAD)
Official title Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
ClinicalTrials.gov ID: NCT07613840
What this study is testing
What is Aspirin?
Aspirin is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for peripheral arterial disease (pad).
Also referred to as Acetylsalicylic Acid; ASA.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore blood flow to their legs. The main questions it aims to answer are: Does the personalized plan lower the rate of blood clots in the treated leg one year after the procedure?
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients with a named arterial extremity injury or named vessel revascularization for atherosclerosis requiring open and/or closed revascularization.
- Patients at the age of 18 or older
You likely can't join if
- Patients who are younger than 18 years old
- Known pregnancy (females of childbearing potential will have a pregnancy test prior to surgery as per standard of care)
- Prisoners, defined as those who have been directly admitted from a correctional facility.
- No atherosclerosis
- Subject has active stomach ulcers
- Subject has severe hepatic impairment
See the full eligibility criteria
- Patients with a named arterial extremity injury or named vessel revascularization for atherosclerosis requiring open and/or closed revascularization.
- Patients at the age of 18 or older
- Patients who are younger than 18 years old
- Known pregnancy (females of childbearing potential will have a pregnancy test prior to surgery as per standard of care)
- Prisoners, defined as those who have been directly admitted from a correctional facility.
- No atherosclerosis
- Subject has active stomach ulcers
- Subject has severe hepatic impairment
- Subject has a recent history of intracranial hemorrhage. If the patient has a history of cerebral hemorrhage with no new central nervous system disease of \>1 year, the study team will consult with the
The study team makes the final eligibility decision.
Where it's taking place
- Boston, Massachusetts, United States
- Salem, Massachusetts, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Boston, Massachusetts, United States; Salem, Massachusetts, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.